I thank the House for their attention to this bill that will make a difference to more vulnerable parts of our population who seek the further assurance of an additional dose of an appropriate COVID vaccine. Our vaccination programme is dominated by the Pfizer vaccine—the brand name Comirnaty—but we have had two or three other vaccines as well, as part of our programme. AstraZeneca is probably the next most used, and there's Novavax as well. So this bill simply allows the director-general, through an appropriate notice and on appropriate assurances, to approve a further dose being given, and the basis of that dose as well. This simply reflects the fact that there is international evidence that, for some parts of the population, the vaccine wans in efficacy. For those who are concerned about that, and where it's medically appropriate, they can get an additional dose of that.